TR200103411T2 - Amlodipin ve atorvastatinin müşterek tuzu. - Google Patents

Amlodipin ve atorvastatinin müşterek tuzu.

Info

Publication number
TR200103411T2
TR200103411T2 TR2001/03411T TR200103411T TR200103411T2 TR 200103411 T2 TR200103411 T2 TR 200103411T2 TR 2001/03411 T TR2001/03411 T TR 2001/03411T TR 200103411 T TR200103411 T TR 200103411T TR 200103411 T2 TR200103411 T2 TR 200103411T2
Authority
TR
Turkey
Prior art keywords
common salt
amlodipine
atorvastatin
risk
methods
Prior art date
Application number
TR2001/03411T
Other languages
English (en)
Inventor
Chang George
Seiichi Hamanaka Ernest
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of TR200103411T2 publication Critical patent/TR200103411T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Bu bulus amlodipin ve atorvastatinin müsterek bir tuzu, bunun farmasötik kompozisyonlari ve memeli yaratiklarda anjin pektoris, ateroskleroz ve kombine hipertansiyon ile hiperlipideminin böyle bir müsterek tuz ve kompozisyonlar ile tedavisine yönelik metodlarla ilgilidir. Bu bulus, ayni zamanda, böyle bir müsterek tuz ve kompozisyonlarin uygulanmasi sureti ile insanlar da dahil olmak üzere kardiyak riski semptomlari sergileyen bir memeli yaratikta kardiyak riskinin yöneltilmesine yönelik metodlarla da ilgilidir.
TR2001/03411T 1999-05-27 2000-05-08 Amlodipin ve atorvastatinin müşterek tuzu. TR200103411T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13626999P 1999-05-27 1999-05-27

Publications (1)

Publication Number Publication Date
TR200103411T2 true TR200103411T2 (tr) 2002-04-22

Family

ID=22472108

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/03411T TR200103411T2 (tr) 1999-05-27 2000-05-08 Amlodipin ve atorvastatinin müşterek tuzu.

Country Status (36)

Country Link
US (1) US6262092B1 (tr)
EP (1) EP1180097B1 (tr)
JP (1) JP2003500473A (tr)
KR (1) KR20020019450A (tr)
CN (1) CN1373753A (tr)
AP (1) AP2001002347A0 (tr)
AR (1) AR028994A1 (tr)
AT (1) ATE367376T1 (tr)
AU (1) AU4138200A (tr)
BG (1) BG106128A (tr)
BR (1) BR0011008A (tr)
CA (1) CA2375225C (tr)
DE (1) DE60035581T2 (tr)
EA (1) EA200101132A1 (tr)
EE (1) EE200100632A (tr)
ES (1) ES2287009T3 (tr)
GT (1) GT200000077A (tr)
HN (1) HN2000000050A (tr)
HR (1) HRP20010857A2 (tr)
HU (1) HUP0202070A3 (tr)
IL (1) IL145837A0 (tr)
IS (1) IS6133A (tr)
MA (1) MA26739A1 (tr)
MX (1) MXPA01012126A (tr)
NO (1) NO20015757L (tr)
OA (1) OA11951A (tr)
PA (1) PA8494501A1 (tr)
PE (1) PE20010168A1 (tr)
PL (1) PL352828A1 (tr)
SK (1) SK16802001A3 (tr)
TN (1) TNSN00110A1 (tr)
TR (1) TR200103411T2 (tr)
UA (1) UA56363C2 (tr)
UY (1) UY26163A1 (tr)
WO (1) WO2000073271A1 (tr)
ZA (1) ZA200109693B (tr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
US20050119270A1 (en) * 2000-08-04 2005-06-02 Mason R. P. Synergistic effect of amlodipine and atorvastatin on aortic endothelial cell nitric oxide release
US6835742B2 (en) * 2000-08-04 2004-12-28 R. Preston Mason Synergistic effect of amlodipine and atorvastatin on cholesterol crystal formation inhibition and aortic endothelial cell nitric oxide release
GB0027410D0 (en) * 2000-11-09 2000-12-27 Pfizer Ltd Mutual prodrug of amlodipine and atorvastatin
US6737430B2 (en) 2000-11-09 2004-05-18 Pfizer, Inc. Mutual prodrug of amlodipine and atorvastatin
PE20030324A1 (es) * 2001-07-31 2003-04-03 Warner Lambert Co Composiciones farmaceuticas de amlodipina y atorvastatina
DE10140421A1 (de) * 2001-08-17 2003-03-06 Bayer Ag Neue Kombination
US6680334B2 (en) 2001-08-28 2004-01-20 Pfizer Inc Crystalline material
WO2003035046A2 (en) * 2001-10-18 2003-05-01 Novartis Ag Salts formed of an at1-receptor antagonist and a cardiovascular agent
CN1152013C (zh) * 2001-11-22 2004-06-02 张喜田 一类左旋氨氯地平盐的水合物及其制剂
US7670612B2 (en) 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
US6699892B2 (en) 2002-06-04 2004-03-02 Yung Shin Pharmaceutical Industrial Co., Ltd. Pharmaceutically acceptable salt of amlodipine and method of preparing the same
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
KR100462304B1 (ko) * 2002-07-30 2004-12-17 씨제이 주식회사 암로디핀의 유기산염
KR100496436B1 (ko) * 2002-07-30 2005-06-20 씨제이 주식회사 암로디핀의 유기산염
WO2005097191A2 (en) * 2004-04-04 2005-10-20 Sepracor Inc. COMBINATIONS COMPRISING (S)- AMLODIPINE AND A HMG-CoA REDUCTASE INHIBITOR OR CHOLESTEROL ABSORPOTION INHIBITOR OR BOTH, AND METHODS FOR REDUCING HYPERTENSION
CA2499047A1 (en) * 2005-03-01 2006-09-01 Apotex Pharmachem Inc. Process for producing atorvastatin hemicalcium
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
US20100029743A1 (en) * 2006-09-27 2010-02-04 Dr. Reddy's Laboratories Ltd. Atorvastatin pharmaceutical compositions
GB0624087D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
US20090042849A1 (en) * 2006-12-06 2009-02-12 Yochai Birnbaum Phosphorylation of 5-lipoxygenase at ser523 and uses thereof
JP2018516624A (ja) * 2015-04-15 2018-06-28 コンシーヴァルブ エルエルシー 自然心臓弁、ステント装着された心臓弁またはバイオプロテーゼの狭窄、閉塞または石灰化を抑制するためのデバイスおよび方法
CN105012258B (zh) * 2015-08-06 2017-11-03 北京嘉林药业股份有限公司 阿托伐他汀钙和氨氯地平片剂的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK161312C (da) 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5155120A (en) 1991-01-14 1992-10-13 Pfizer Inc Method for treating congestive heart failure
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.

Also Published As

Publication number Publication date
PE20010168A1 (es) 2001-02-10
CA2375225C (en) 2007-02-20
BR0011008A (pt) 2002-02-19
KR20020019450A (ko) 2002-03-12
HUP0202070A2 (en) 2002-10-28
HN2000000050A (es) 2001-02-02
DE60035581T2 (de) 2008-04-17
ES2287009T3 (es) 2007-12-16
EP1180097A1 (en) 2002-02-20
AP2001002347A0 (en) 2001-12-31
GT200000077A (es) 2001-11-16
NO20015757D0 (no) 2001-11-26
TNSN00110A1 (fr) 2005-11-10
IS6133A (is) 2001-10-30
SK16802001A3 (sk) 2003-02-04
AR028994A1 (es) 2003-06-04
OA11951A (en) 2006-04-13
MXPA01012126A (es) 2002-06-04
NO20015757L (no) 2001-12-20
WO2000073271A1 (en) 2000-12-07
HUP0202070A3 (en) 2003-03-28
BG106128A (en) 2002-05-31
CA2375225A1 (en) 2000-12-07
ZA200109693B (en) 2002-11-26
DE60035581D1 (de) 2007-08-30
EA200101132A1 (ru) 2002-04-25
CN1373753A (zh) 2002-10-09
MA26739A1 (fr) 2004-12-20
UY26163A1 (es) 2000-12-29
UA56363C2 (uk) 2003-05-15
EP1180097B1 (en) 2007-07-18
IL145837A0 (en) 2002-07-25
PL352828A1 (en) 2003-09-08
ATE367376T1 (de) 2007-08-15
HRP20010857A2 (en) 2003-02-28
JP2003500473A (ja) 2003-01-07
PA8494501A1 (es) 2002-07-30
EE200100632A (et) 2003-02-17
AU4138200A (en) 2000-12-18
US6262092B1 (en) 2001-07-17

Similar Documents

Publication Publication Date Title
TR200103411T2 (tr) Amlodipin ve atorvastatinin müşterek tuzu.
CY1105108T1 (el) Θepαπευτικοι συνδυασμοι που πepιλαμβανουν αμλοδιπινη και ατορβαστατινη
TR200103391T2 (tr) Amlodipin ve atorvastatinin ön ilaçları.
HUP0004318A2 (hu) Atorvastatint és egy vérnyomáscsökkentő szert tartalmazó gyógyszerkészítmény
TR200000562T2 (tr) Amlodifin ve bir statin bileşiği içeren bileşim terapisi
FR2780730B1 (fr) Compositions biphasiques injectables, notamment utiles en chirurgies reparatrice et esthetique
ID29994A (id) Komposisi farmasi untuk melawan ccr5 terdiri dari turunan anilida
AR034925A1 (es) Composiciones farmaceuticas de amlodipina y atorvastatina
DE69401823D1 (de) Indolin derivate als 5ht2c antagonisten
TR200101470T2 (tr) Farmasötik bileşim terkipleri.
TR200000419T2 (tr) Feksofenadin ve türevlerinin biyo elde edilebilirliklerinin arttırılması yöntemi.
ECSP003493A (es) Profarmacos mutuos de amlodipino y atorvastatina
ECSP003497A (es) Sal mutua de amlodipino y atorvastatina
ECSP982647A (es) Terapia de combinacion
FI4734U1 (fi) Rimakuorma sahatavarasta ja sahalaitos
DE10082412D2 (de) Lichtschrankenanordnung mit Strahlteiler
IT1313237B1 (it) Componente strutturale multifunzionale per quadri elettrici,centralini e simili.
ECSP961763A (es) N-(indol -2-carbonil) glicinamidas sustituidas y derivados como agentes antidiabeticos